SERUM-CHOLESTEROL AS A PROGNOSTIC FACTOR AFTER MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY

被引:143
作者
WONG, ND [1 ]
WILSON, PWF [1 ]
KANNEL, WB [1 ]
机构
[1] FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA
关键词
D O I
10.7326/0003-4819-115-9-687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the relation between serum cholesterol levels and the long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality in persons who recover from myocardial infarction. Design: Prospective, longitudinal study. Setting: A geographically defined population-based cohort of adults participating in the Framingham Heart Study. Patients: Men (n = 260) and women (n = 114), 33 to 88 years of age (mean age, 62 years), who had a history of myocardial infarction. Measurements: A complete physical examination, including electrocardiographic evaluation, blood pressure measurement, height and weight measurements, determination of smoking habits, and casual determinations of blood glucose and serum cholesterol, was done approximately 1 year after recovery from initial myocardial infarction. Patients were followed after infarction for the occurrence of reinfarction or death (mean follow-up, 10.5 years; range, 0.8 to 31.6 years). Main Results: The mean cholesterol level after infarction was 5.21 mmol/L (242.8 mg/dL); 20% of patients had levels below 5.17 mmol/L (200 mg/dL), and 22% had levels of 7.11 mmol/L (275 mg/dL) or more. Compared with patients who had cholesterol levels below 5.17 mmol/L, patients with levels of 7.11 mmol/L or more were at increased risk for reinfarction (relative risk, 3.8; 95% CI, 1.6 to 8.7), death from coronary heart disease (relative risk, 2.6; CI, 1.4 to 4.8), and all-cause mortality (relative risk, 1.9; CI, 1.2 to 2.9) based on multivariate Cox regression analyses adjusted for other coronary risk factors. Intermediate cholesterol levels (5.17 mmol/L to 7.11 mmol/L) were generally not associated with increased risk. The association between elevated serum cholesterol and increased risk was strongest in men; however, elevated cholesterol levels were found to be most strongly related to death from coronary disease and to all-cause mortality in persons who were 65 years of age or more. Conclusions: Patients who have recovered from a myocardial infarction and who have high cholesterol levels are at an increased long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality. Our results confirm the prognostic value of cholesterol levels measured after myocardial infarction and support the role of lipid management in this population.
引用
收藏
页码:687 / 693
页数:7
相关论文
共 28 条
[1]  
ABELL LL, 1952, J BIOL CHEM, V195, P357
[2]   CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY [J].
ANDERSON, KM ;
CASTELLI, WP ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16) :2176-2180
[3]   41-MONTH FOLLOW-UP OF RISK-FACTORS CORRELATED WITH NEW CORONARY EVENTS IN 708 ELDERLY PATIENTS [J].
ARONOW, WS ;
HERZIG, AH ;
ETIENNE, F ;
DALBA, P ;
RONQUILLO, J .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1989, 37 (06) :501-506
[4]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[5]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[6]   EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
VARCO, RL ;
MATTS, JP ;
LONG, JM ;
FITCH, LL ;
CAMPBELL, GS ;
PEARCE, MB ;
YELLIN, AE ;
EDMISTON, WA ;
SMINK, RD ;
SAWIN, HS ;
CAMPOS, CT ;
HANSEN, BJ ;
TUNA, N ;
KARNEGIS, JN ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
BISSETT, JK ;
WEBER, FJ ;
STEVENSON, JW ;
LEON, AS ;
CHALMERS, TC .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955
[7]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[8]  
CARLSON LA, 1988, ACTA MED SCAND, V223, P405
[9]   BENEFICIAL-EFFECTS OF COLESTIPOL-NIACIN ON CORONARY ATHEROSCLEROSIS - A 4-YEAR FOLLOW-UP [J].
CASHINHEMPHILL, L ;
MACK, WJ ;
POGODA, JM ;
SANMARCO, ME ;
AZEN, SP ;
BLANKENHORN, DH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (23) :3013-3017
[10]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838